ptvg-hp
Vaccineexperimental
Clinical trial activity
4 trials · 7 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started Mar 1, 2005 (NCT00582140)
Timeline
Indications
Mechanism of action
- Prostatic acid phosphataseImmunity, active
ACP3 immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- ptvg-hp
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04090528 | Phase 2 | Sep 30, 2019 | Madison Vaccines Incorporated, Merck, Prostate Cancer Foundation, University of Wisconsin |
| NCT03600350 | Phase 2 | Sep 10, 2018 | Bristol-Myers Squibb, Madison Vaccines Incorporated, University of Wisconsin |
| NCT00849121 | Phase 2 | Mar 1, 2009 | National Cancer Institute (NCI), University of Wisconsin |
| NCT00582140 | Phase 1 | Mar 1, 2005 | Department of Defense, University of Wisconsin |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (7)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| University of Wisconsin | Academic/Hospital | 4 | 4 | 2 | 2005 |
| Madison Vaccines Incorporated | For profit | 2 | 0 | 1 | 2018 |
| Bristol-Myers Squibb | For profit | 1 | 0 | 1 | 2018 |
| Department of Defense | Government | 1 | 0 | 1 | 2005 |
| Merck | For profit | 1 | 0 | 1 | 2019 |
| National Cancer Institute (NCI) | Government | 1 | 0 | 1 | 2009 |
| Prostate Cancer Foundation | Academic/Hospital | 1 | 0 | 1 | 2019 |
7 organizations
Page 1 / 1